CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CanSino Biologics Inc. has announced the initiation of Phase II/III clinical trials for its new Tdcp Adolescent and Adult booster vaccine, aimed at addressing the absence of an approved diphtheria, tetanus, and acellular pertussis booster for individuals aged six and above in China. This development promises to fill a crucial gap in the domestic market and enhance vaccine stability with improved manufacturing processes. Investors are advised to remain cautious while dealing in company shares.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
